Plus Therapeutics Stock Price and Value Analysis

Should you buy Plus Therapeutics stock? (NasdaqCM:CYTX). Let's see how it does in our automated value investing analysis system.

CYTX Free Cash Flow Trend

Free Cash Flow trendline for CYTX
Free Cash Flow trendline for Plus Therapeutics

Hmm, we can't give any reliable projection for Plus Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company has stable growth.
  • This company is solid.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the CYTX Numbers

CYTX Price
(Plus Therapeutics stock price per share)
PE Ratio versus Sector 100% lower than other Healthcare stocks
PE Ratio versus Industry 100% lower than other Biotechnology stocks
Cash Yield -445.48%
Free Cash Flow Jitter 24%

Is Plus Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Plus Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy CYTX Stock?

Does Plus Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.